Miracor Medical Systems increases clinical and commercial activities in the UK

Miracor UK Ltd to open Sales and Education Center in Manchester Science Parks

Miracor Medical Systems announced today that it will further increase its activities in the UK, led by its newly founded sales subsidiary in Manchester. To date, several leading centers in the UK are already actively using the PICSO Impulse System to treat patients with myocardial infarction.

“We are very pleased to see how quickly our therapy for acute MI patients has been integrated into the clinical setting,” says Ludwig Gold, CEO of Miracor Medical Systems; “With our newly founded subsidiary, we will be able to directly serve our UK customer base and enlarge our activities in this key market”.

Miracor is currently conducting two clinical studies in the UK, further evaluating the effectiveness of PICSO Therapy in myocardial infarction patients, used in daily clinical practice during standard PCI. Recently presented data show that PICSO, as an adjuvant treatment to primary Percutaneous Coronary Intervention (pPCI), may significantly reduce infarct size in patients presenting with acute ST-Segment Elevation Myocardial Infarction (STEMI).

About Miracor Medical Systems GmbH
Miracor Medical Systems GmbH (www.miracormedical.com) is an Austrian medical device company dedicated to improve clinical outcome of patients with impaired cardiac function. So far, Miracor has raised over EUR 24 million in venture capital and public funding. Major investors include Earlybird Venture Capital, Delta Partners, SHS, BioMedInvest, and aws Founders Fund.
The Miracor PICSO® (Pressure-controlled Intermittent Coronary Sinus Occlusion) Impulse System is designed to treat acute ST-Segment Elevation Myocardial Infarction (‘STEMI’) patients and less severe Non-ST-Segment Elevation Myocardial Infarction (‘NSTEMI’) patients by improving myocardial perfusion in complement with percutaneous coronary intervention (PCI). PICSO is applied during PCI and designed to intermittently block the coronary sinus, a large vessel that collects blood from the heart muscle (myocardium), thereby increasing perfusion of the myocardium and reducing injury resulting from myocardial infarction.

NOTE: The CE marked PICSO® Impulse System is approved for sale in Europe.
It is currently not approved for use in the United States.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.